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Seven members of a family of cytokine-inducible
proteins have been identified, a number of which have
been shown to act as negative regulators of cytokine
action. All of these proteins contain a central Src
homology 2 domain, as well as conserved motifs in
their carboxy-terminal regions. 
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Cytokines are a broad array of molecules that mediate
signals important for many biological functions, including
growth, differentiation, and apoptosis. Cytokines can exert
actions on the cells that produce them (autocrine signals)
or on other cells (paracrine signals). Type I cytokines have
similar four α-helical bundle structures and are also
referred to as ‘up–up–down–down’ helical cytokines
because of the topological orientation of the sequential α
helices. In addition to the similarity in structure of type I
cytokines, the receptors of these molecules form a family
and share certain signaling pathways, most notably the
pathway involving Janus kinases (JAKs) and signal trans-
ducers and activators of transcription (STATs). The group
of type II cytokines includes both interferon (IFN)-α/β
and IFN-γ as well as interleukin 10 (IL-10). These
cytokines have different structures from the type I
cytokines, but they also exert their actions, at least in part,
via the JAK–STAT pathway.
Over the years, the majority of investigations on cytokines
have focused on the mechanisms by which they exert
their actions. It is clear, however, that the actions of all of
the cytokines are limited in both magnitude and duration,
and an understanding of the mechanisms by which their
actions are negatively controlled is therefore essential.
Control of cytokine signaling can occur at a number of reg-
ulatory points: the regulation of the production of a
cytokine or its receptor; the regulation of the degradation
of a cytokine or its receptor; or the control of the
phosphorylation/dephosphorylation of substrates (includ-
ing the cytokine receptors themselves, JAKs and other
substrates).
Recent reports revealed a new family of proteins that are
induced by cytokines but then inhibit cytokine action.
The first member of this family was denoted as CIS, for
cytokine-induced Src homology 2 (SH2)-containing
protein [1]. The CIS gene was cloned originally as an
immediate early gene that was induced by IL-2, IL-3 and
erythropoietin (EPO). CIS was noted to associate with the
tyrosine-phosphorylated EPO receptor (EPOR) and the
IL-3 receptor β chain following stimulation with EPO or
IL-3, respectively [1] (Figure 1). The presence of an SH2
domain in CIS could therefore explain the basis for this
recruitment, although direct SH2–phosphotyrosine inter-
actions between CIS and these receptors have yet to be
demonstrated. From a functional perspective, it was noted
that, when overexpressed, CIS could function as a nega-
tive regulator of IL-3-induced proliferation, although the
mechanism of action of CIS was unclear [1]. One possi-
bility is that CIS acts as an adaptor protein linking
Figure 1
Schematic of cytokine signaling, showing that CIS is regulated by
STATs and is an inhibitor of STAT activation. CIS is shown associated
with a receptor component, as it is known that CIS can associate with
the EPO receptor and IL-3 receptor β chain, as discussed in the text.
Two possible sites of action are shown for CIS. SOCS-1/JAB/SSI-1
(shown here as JAB out of space consideration) is shown to interact
with JAKs and to inhibit their action.
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cytokine receptors to other molecules involved in growth
inhibition. This idea is based on the presence of an SH2
domain in the central portion of the molecule and amino-
terminal and carboxy-terminal regions that are rich in
proline and leucine residues that can be involved in medi-
ating protein–protein interactions. Alternatively, it was
also suggested that CIS might function by directly block-
ing phosphotyrosine motifs on receptors, preventing them
from coupling to stimulatory signaling pathways [1].
Finally, given that CIS was observed to have a relatively
short half-life, a third potential role for CIS was as a scav-
enger of tyrosine-phosphorylated proteins, targeting them
for degradation [1].
Several observations have linked CIS to JAK–STAT path-
ways. First, induction of CIS in response to granulocyte-
macrophage colony-stimulating factor (GM-CSF) and
EPO is dependent on the presence of membrane-proxi-
mal regions of the common β chain, βc — a receptor chain
that is a shared component of the receptors for IL-3, IL-5
and GM-CSF — and EPOR; these regions mediate JAK
activation [1]. Second, the CIS promoter contains two
pairs of tandem TTCNNNGAA motifs that are capable of
binding Stat5, and a CIS-promoter reporter construct was
induced by EPO in cells transfected with plasmids
expressing EPOR and Stat5 [2]. In addition to the regula-
tion of CIS production by the JAK–Stat5 pathway, it was
interesting that CIS could negatively modulate Stat5 acti-
vation [2], suggesting that a possible negative-feedback
loop operates. The JAK–STAT pathway does not seem to
be the only pathway responsible for CIS induction,
however, as CIS can be induced by tumor necrosis factor α
(TNF-α) [3], a cytokine that is not known to activate JAKs
or STATs.
Excitement over CIS increased tremendously earlier this
year with the publication of three papers in Nature that
reported the existence of CIS-related proteins. Remark-
ably, one of these proteins was cloned in three different
labs by three entirely different experimental approaches.
Starr et al. [3] cloned suppressor of cytokine signaling-1
(SOCS-1) as an inhibitor of IL-6-mediated differentiation
and growth arrest of murine monocytic leukemic M1 cells;
Endo et al. [4] cloned the same protein as a JAK-binding
protein (JAB) that could interact with the catalytic (JH1)
domain of Jak2; and Naka et al. [5] identified this protein
using an antibody intended to be specific for SH2 domains
of STATs — but which did not turn out to be completely
specific — and found that it was not a STAT protein but
instead was STAT-induced STAT inhibitor-1 (SSI-1).
Collectively, the papers demonstrate that SOCS-
1/JAB/SSI-1 is a potent inhibitor of IL-6 signaling, includ-
ing IL-6-induced tyrosine phosphorylation of a
component of its receptor, gp130, and Stat3. Interestingly,
this CIS-related protein can interact not only with Jak2
but also with Jak1, Jak3 and Tyk2, and is an inhibitor of
JAK catalytic activity (Figure 1) [4,5]. Consistent with its
potential specificity for inhibiting JAKs, it did not inhibit
fibroblast growth factor-mediated proximal events in
NIH3T3 cells, such as receptor autophosphorylation, and
phosphorylation of Shc and extracellular-signal-regulated
kinase 2 (Erk2) [4].
Biological roles of CIS family proteins
A comparison of CIS, SOCS-1/JAB/SSI-1, and two other
members of this family reveals a number of differences in
their expression patterns. First, SOCS-1/JAB/SSI-1 is par-
ticularly highly expressed in thymus, and also is substan-
tially expressed in spleen and lung, whereas CIS is more
ubiquitously expressed [3]. Second, CIS can be induced
by a wider range of cytokines than those that induce the
other family members (Table 1) [3]: whereas CIS was orig-
inally noted to be induced by IL-2, IL-3 and EPO [1], it is
now clear that CIS is also induced by IL-4, IL-7, IL-13,
thrombopoietin (TPO), granulocyte colony-stimulating
factor (G-CSF), GM-CSF, IFN-γ, TNF-α, IL-1,
macrophage colony-stimulating factor (M-CSF), IL-6, IL-
12 and leukemia inhibitory factor (LIF) [3]. In contrast,
only a subset of these stimuli induce SOCS-1/JAB/SSI-1;
for example, in bone marrow cells SOCS-1/JAB/SSI-1 is
not induced by TNF-α, IL-1 and IL-7 [3]. Two additional
members of the CIS family, SOCS-2 and SOCS-3, are
somewhat more broadly expressed than SOCS-1/JAB/SSI-
1 [3,6], with SOCS-3 showing the same pattern of
induction as CIS [3].
On the basis of studies in vitro using cytokine-responsive
cell lines, CIS and SOCS-1/JAB/SSI-1 appear to be nega-
tive regulators, as noted above (see Table 2 for a
summary of known actions). First, forced overexpression
of CIS in Ba/F3 cells results in decreased IL-3-induced
proliferation [1], presumably as a result of the inhibition
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Table 1
Cytokines that induce the CIS family members in bone marrow cells.
CIS SOCS-1/JAB/SSI-1 SOCS-2/SSI-2/CIS2 SOCS-3/SSI-3/CIS3
IL-1 + – + +
IL-2 + – +/– +
IL-3 ++ + + +
IL-4 ++ + + +
IL-6 + –* +/– +
IL-7 + – +/– +
IL-13 + ++ – +
LIF +/– +/– + +
GM-CSF ++ + + +
G-CSF + – + ++
M-CSF + – – ++
EPO + + ++ +
TPO + – + +
IFN-γ ++ ++ + ++
*Although IL-6 does not induce SOCS-1/JAB/SSI-1 in bone marrow cells, it
induces this CIS family member in murine liver. Abbreviations as in the text.
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of transcriptional activity of several transcriptional targets
of cytokine signaling. Second, CIS can inhibit Stat5-
mediated signaling [2] and transcription from the c-fos
promoter (M.J.A. and W.J.L., unpublished observations).
Third, SOCS-1/JAB/SSI-1 completely abrogates the
macrophage differentiation of the murine monocytic
leukemic M1 cells in response to IL-6, LIF, oncostatin M
and IFN-γ [3], and increases the proliferation of undiffer-
entiated M1 cells [5]. This inhibitory effect seems to be
specific to cytokine signaling as dexamethasone-induced
differentiation is only partially inhibited and not totally
abrogated by SOCS-1/JAB/SSI-1 [3]. Fourth, like CIS,
SOCS-1/JAB/SSI-1 can inhibit transcription from the c-fos
promoter [4] in addition to the activation of Stat3 [3]. The
anti-proliferative activity of CIS and the inhibition of dif-
ferentiation by JAB imply that dysregulation of these pro-
teins may have a role in proliferative disorders and
malignancies, particularly in the hematopoietic system.
This hypothesis is consistent with the putative mapping
of the human CIS gene to 3p21 (based on mapping of the
murine Cis gene to chromosome 9), a region that is fre-
quently deleted or rearranged in renal and bronchogenic
malignancies (discussed in [1]).
SOCS-2 (also denoted as SSI-2 or CIS2) and SOCS-3 (also
denoted as SSI-3 or CIS3) have been cloned in both
murine [3] and human [6,7] systems. Moreover, three
additional members of this family, denoted CIS4, CIS5
Table 2
Known actions of the different CIS family members*.
CIS family member Action
CIS (now also denoted as CIS1): Associates with IL-3Rβ and EPOR; negatively regulates IL-3-induced proliferation; inhibits STAT induction.
SOCS-1/JAB/SSI-1: Associates with all four mammalian JAKs and inhibits their catalytic activity; inhibits IL-6-mediated differentiation and growth arrest of
M1 cells; inhibits IL-6-induced phosphorylation of gp130 and Stat3; inhibits IL-2-mediated and IL-3-mediated c-fos promoter 
activity; inhibits EPO-mediated Stat5 activity.
SOCS-2/SSI-2/CIS2: Inhibits LIF-mediated differentiation and growth arrest of M1 cells†; inhibits LIF-induced tyrosine phosphorylation of Stat3†.
SOCS-3/SSI-3/CIS3: Associates with the JH1 domain of Jak2 and partially inhibits its catalytic activity; inhibits LIF-mediated differentiation and growth 
arrest of M1 cells; inhibits LIF-induced tyrosine phosphorylation of Stat3.
CIS4, CIS5, CIS6 None reported so far.
*Given the wide range of cytokines that activate different CIS family proteins and their broad tissue distribution, it is likely that broader ranges of action will be found for
each of these molecules. †These results are as reported in [6], but there is disagreement about the ability of SOCS-2/SSI-2/CIS2 to exert these effects [7].
Abbreviations as in the text.
Figure 2
Schematic of CIS family proteins, depicting
the lengths of the amino-terminal (NT), SH2,
and carboxy-terminal (CT) domains. The
SOCS box/CH domain is shown as part of
the CT domain.
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and CIS6, have been identified [7]. Whereas SOCS-
1/JAB/SSI-1 is highly expressed in thymus, spleen, small
intestine and peripheral blood leukocytes (PBL), SOCS-
2/SSI-2/CIS2 is highly expressed in heart, placenta, lung,
kidney and prostate and SOC-3/SSI-3/CIS3 is expressed
in heart, placenta, lung, skeletal muscle and PBL. The
differences in tissue distributions indicate that these CIS
proteins might regulate different functions. Although both
SOCS-2/SSI-2/CIS2 and SOC-3/SSI-3/CIS3 have been
reported to inhibit LIF-induced tyrosine phosphorylation
of Stat3 as well as LIF-induced growth arrest of M1 cells
[6], some controversy remains regarding the actions of
SOCS-2/SSI-2/CIS2 (see Table 2) [6,7]. The functions of
CIS4, CIS5, and CIS6 remain unclear.
Functional domains of CIS family proteins
The functional domains of CIS proteins have been poorly
studied. The isolated SH2 domain of SOCS-1/JAB/SSI-1)
failed to inhibit autophosphorylation of Jak2 in 293 cells
and had no inhibitory effect on the transcriptional activity
of the c-fos promoter in Ba/F3 cells [4]. These data suggest
a crucial role for the regions that are located amino-termi-
nal or carboxy-terminal to the SH2 domain.
As noted above, both the amino-terminal and carboxy-
terminal domains of CIS are rich in proline and leucine
residues (10 Pro and 11 Leu in the amino-terminal 81
amino acids; 11 Pro and 12 Leu in the 80 carboxy-terminal
amino acids), as are some of the other CIS family proteins.
It is noteworthy that there is no significant homology
between the family members in the amino-terminal
region, suggesting either that this region is not function-
ally critical or instead that it might confer substrate speci-
ficity to the respective family member. Despite the lack
of homology in the primary structure, however, the ter-
tiary structures of the amino-terminal domains might be
similar, although SOCS-2/SSI-2/CIS2 and SOCS-3/SSI-
3/CIS3 have relatively short amino-terminal regions of
approximately 45 amino acids, in contrast to the longer
amino-terminal regions of CIS, SOCS-1/JAB/SSI-1, and
CIS4 (Figure 2). Like the amino-terminal regions, the
carboxy-terminal regions vary substantially in length, with
human CIS (81 residues) and SOCS-3/SSI-3/CIS3 (84
residues) having longer carboxy-terminal regions, in con-
trast to the shorter regions of human SOCS-2/SSI-2/CIS2
(55 residues) and SOCS-1/JAB/SSI-1 (50 residues); nev-
ertheless, the carboxy-terminal regions are more con-
served than the amino-terminal regions. The carboxyl
termini of the CIS family members contain a 40–50
amino-acid region of homology denoted as a SOCS box
[3], or CH (CIS homology) domain (see Figure 3) [7];
however, the function of this region remains unknown.
All the CIS family proteins share about 55% identity in
their SH2 domains. 
A number of major questions remain concerning this
family of proteins. First, are all of these molecules
inhibitory? Do any have both inhibitory and agonistic
actions? Second, how do they exert their actions? CIS
can interact with certain receptor molecules; for how
many of these proteins is this the case? SOCS-1/SSI-
1/JAB can interact with JAK family members: is this true
for other members of the CIS family? Are these proteins
adaptor molecules? If so, what types of proteins do they
recruit? Given that some of these proteins can diminish
phosphorylation, is this solely due to inhibitory effects
on kinases or do these proteins recruit phosphatases as
well? Do the CIS proteins block phosphotyrosine-
docking sites for critical signaling pathways? Although
possible, this seems less likely in view of the inability of
the isolated SH2 domain of SOCS-1/JAB/SSI-1 to inhibit
cytokine action [4]. Do they promote degradation of
receptors or other molecules with which they might
interact? What are the roles of the regions amino-termi-
nal and carboxy-terminal to the SH2 domain? Third,
what signaling pathways are inhibited? Clearly, there are
data related to the JAK–STAT pathways and to the c-fos
promoter for some of these proteins, but are other
kinases and signaling pathways also affected? Fourth,
how many more members of this family exist in addition
to the seven that have been reported? Will there be as
many or even more CIS family members as there are
STATs? Also, which CIS family members are important
for which cytokines?
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Figure 3
Alignment of the SOCS boxes/CH domains of
CIS family proteins.
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In summary, an exciting new class of cytokine inhibitors
that contain divergent amino-terminal regions, central
SH2 domains and partially conserved carboxy-terminal
regions has now been recognized. These proteins are
rapidly induced by a number of cytokines and at least
three members (CIS, SOCS-1/JAB/SSI-1 and SOCS-
3/SSI-3/CIS3) have been shown to interfere with
JAK–STAT signaling pathways. In addition to the need to
further understand their mechanism(s) of action, it
remains unclear to what degree these proteins have over-
lapping or distinct functions. The preparation of knockout
mice in which each of these molecules is individually
deleted, as well as knockout mice in which combinations
of these proteins are deleted, should help to clarify the
distinct functions of each of these proteins.
Nomenclature
A final word on nomenclature seems relevant. Currently,
these proteins are being referred to using CIS, SOCS, JAB
and SSI nomenclatures. Although all of these names have
their own merit, the sooner agreement is reached upon
this nomenclature issue, the easier it will be for the scien-
tific community to understand the many studies that are
likely to be published on this exciting family of molecules.
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